Skip to main content
The Actuary: The magazine of the Institute and Faculty of Actuaries - return to the homepage Logo of The Actuary website
  • Search
  • Visit The Actuary Magazine on Facebook
  • Visit The Actuary Magazine on LinkedIn
  • Visit @TheActuaryMag on Twitter
Visit the website of the Institute and Faculty of Actuaries Logo of the Institute and Faculty of Actuaries

Main navigation

  • News
  • Features
    • General Features
    • Interviews
    • Students
    • Opinion
  • Topics
  • Knowledge
    • Business Skills
    • Careers
    • Events
    • Predictions by The Actuary
    • Whitepapers
    • Moody's - Climate Risk Insurers series
    • Webinars
    • Podcasts
  • Jobs
  • IFoA
    • CEO Comment
    • IFoA News
    • People & Social News
    • President Comment
  • Archive
Quick links:
  • Home
  • Sections
  • News

Coronavirus breakthrough as dexamethasone cuts deaths by third

Open-access content Tuesday 16th June 2020

iStock-1215319975.jpg

The risk of death among COVID-19 patients on ventilators has been cut by a third using the widely available steroid dexamethasone in a trial led by scientists from the University of Oxford.

The trial also found dexamethasone to reduce the risk of death among patients receiving oxygen only by one-fifth, although there was no benefit among those who didn't require respiratory support.

England's chief medical officer Chris Whitty said: "This is the most important trial result for COVID-19 so far. 

“Significant reduction in mortality in those requiring oxygen or ventilation from a widely available, safe and well known drug. Many thanks to those who took part and made it happen. It will save lives around the world.”

Dexamethasone is already used for a variety of conditions, such as severe allergies and asthma, and can cost as little as £5.40 to treat a coronavirus patient for one day.

A total of 2,104 patients were randomised to receive dexamethasone 6mg once per day for 10 days in the latest trial, either by mouth or by intravenous injection, and were compared with 4,321 patients randomised to usual care alone.

Based on the results, one death would be prevented by dexamethasone treatment of around eight ventilated patients, or one out of around 25 patients requiring oxygen alone.

The research forms part of the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial, set up in March, which is the world's biggest trial testing existing treatments to see if they work for coronavirus.

‘Dexamethasone is the first drug to be shown to improve survival in COVID-19,” said Peter Horby, professor of emerging infectious diseases at the University of Oxford's Nuffield Department of Medicine.

“This is an extremely welcome result. The survival benefit is clear and large in those patients who are sick enough to require oxygen treatment, so dexamethasone should now become standard of care in these patients.

“Dexamethasone is inexpensive, on the shelf, and can be used immediately to save lives worldwide.”

 

Author: Chris Seekings

Image credit: iStock

 

Also filed in
News
Topics
Health care

You might also like...

Share
  • Twitter
  • Facebook
  • Linked in
  • Mail
  • Print

Latest Jobs

Deputy Head of Capital Modelling

London (Central)
£110000 - £130000 per annum
Reference
144789

Head of Analytics (Actuarial)

London (Central)
£130000 - £165000 per annum
Reference
144788

Pensions Actuarial Analyst - GMP Equalisation

London (Central)
£ dependent upon experience
Reference
143745
See all jobs »
 
 

Today's top reads

 
 

Sign up to our newsletter

News, jobs and updates

Sign up

Subscribe to The Actuary

Receive the print edition straight to your door

Subscribe
Spread-iPad-slantB-june.png

Topics

  • Data Science
  • Investment
  • Risk & ERM
  • Pensions
  • Environment
  • Soft skills
  • General Insurance
  • Regulation Standards
  • Health care
  • Technology
  • Reinsurance
  • Global
  • Life insurance
​
FOLLOW US
The Actuary on LinkedIn
@TheActuaryMag on Twitter
Facebook: The Actuary Magazine
CONTACT US
The Actuary
Tel: (+44) 020 7880 6200
​

IFoA

About IFoA
Become an actuary
IFoA Events
About membership

Information

Privacy Policy
Terms & Conditions
Cookie Policy
Think Green

Get in touch

Contact us
Advertise with us
Subscribe to The Actuary Magazine
Contribute

The Actuary Jobs

Actuarial job search
Pensions jobs
General insurance jobs
Solvency II jobs

© 2023 The Actuary. The Actuary is published on behalf of the Institute and Faculty of Actuaries by Redactive Publishing Limited. All rights reserved. Reproduction of any part is not allowed without written permission.

Redactive Media Group Ltd, 71-75 Shelton Street, London WC2H 9JQ